A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.
式(1)所表示的
吡唑并
嘧啶衍
生物及其药学上可接受的盐,表现出对
MAPKAP-K2的优异抑制活性。因此,含有该化合物作为活性成分的药物预计将对由
MAPKAP-K2介导的疾病具有治疗作用,例如,炎症性疾病、自身免疫性疾病、破坏性骨病、癌症和/或肿瘤生长。